Nathalie Laarakker
Director/Board Member presso OXURION NV
Profilo
Nathalie Laarakker is currently the Chief Financial Officer & Director at Intravacc BV since 2021.
She is also an Independent Non-Executive Director at Oxurion NV since 2023.
Previously, she held the position of Chief Financial Officer & Managing Director at Gadeta BV and Head-Finance at Merus NV.
Ms. Laarakker completed her undergraduate degree at the University of Amsterdam.
Posizioni attive di Nathalie Laarakker
| Società | Posizione | Inizio |
|---|---|---|
| OXURION NV | Director/Board Member | 02/05/2023 |
| Intravacc BV | Director/Board Member | 01/01/2021 |
Precedenti posizioni note di Nathalie Laarakker
| Società | Posizione | Fine |
|---|---|---|
| MERUS N.V. | Corporate Officer/Principal | - |
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Corporate Officer/Principal | - |
Formazione di Nathalie Laarakker
| University of Amsterdam | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| OXURION NV | Health Technology |
| MERUS N.V. | Health Technology |
| Aziende private | 2 |
|---|---|
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
| Intravacc BV |
- Borsa valori
- Insiders
- Nathalie Laarakker
